128 related articles for article (PubMed ID: 11182058)
1. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.
Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K
Oncol Rep; 2001; 8(2):369-72. PubMed ID: 11182058
[TBL] [Abstract][Full Text] [Related]
2. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
[TBL] [Abstract][Full Text] [Related]
3. Expression of the tumor-rejection antigen SART1 in brain tumors.
Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
[TBL] [Abstract][Full Text] [Related]
4. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
5. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
6. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
[TBL] [Abstract][Full Text] [Related]
8. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
[TBL] [Abstract][Full Text] [Related]
9. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
10. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
11. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Tsuji H; Yamashita T; Kaneko S
Int J Cancer; 2006 Mar; 118(5):1194-204. PubMed ID: 16152611
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor-rejection antigens in gynecologic cancers.
Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
[TBL] [Abstract][Full Text] [Related]
13. Expression of the SART1 tumor-rejection antigens in colorectal cancers.
Sasatomi T; Yamana H; Shichijo S; Tanaka S; Okamura T; Ogata Y; Itoh K; Shirouzu K
Dis Colon Rectum; 2000 Dec; 43(12):1754-8. PubMed ID: 11156463
[TBL] [Abstract][Full Text] [Related]
14. Expression of tumor rejection antigens in colorectal carcinomas.
Sasatomi T; Suefuji Y; Matsunaga K; Yamana H; Miyagi Y; Araki Y; Ogata Y; Itoh K; Shirouzu K
Cancer; 2002 Mar; 94(6):1636-41. PubMed ID: 11920522
[TBL] [Abstract][Full Text] [Related]
15. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
Li B; Wang Y; Chen J; Wu H; Chen W
Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
18. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
19. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
